Eisai Co., Ltd.
Fiscal Year 2025 Q3 Financial Results Briefing
For fiscal year 2025 Q3, revenue was JPY 619.9 billion (YoY +3.1%), operating income was JPY 54.5 billion (YoY -1.7%), showing steady progress against full-year forecasts.
Key Figures
- Revenue: JPY 619.9 billion (YoY +3.1%)
- Operating Income: JPY 54.5 billion (YoY -1.7%)
- Pharmaceutical Business Revenue: JPY 610.1 billion (YoY +7.2%)
AI要約
Performance Overview
For fiscal year 2025 Q3, revenue was JPY 619.9 billion (YoY +3.1%), driven by organic growth in the pharmaceutical business. Operating income was JPY 54.5 billion (YoY -1.7%) due to absence of one-off gains/losses, but operating income contribution from the pharmaceutical segment expanded. Progress toward the full-year forecast is steady at 78.5% for revenue and 99.9% for operating income.
Business and Product Trends, and Pipeline
Pharmaceutical business revenue reached JPY 610.1 billion, up 7% YoY. Core products Lenvima (JPY 258.1 billion, +4% YoY), Dayvigo (JPY 47.7 billion, +18%), and Rekenvi (JPY 61.8 billion, +109%) showed strong growth. Investments were made for new product launches in Europe and Japan to strengthen the oncology pipeline. Initiatives to maximize product value are progressing, including SC-AI (subcutaneous injection form of Rekenvi) and diagnostic efficiency improvements using BBM.
